Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer

Inclusion Criteria: * Performance status of 0 to 1 on the Eastern Cooperative Oncology Group (ECOG) Scale. * Previously untreated, histological documented, inoperable stage IIIA or IIIB squamous cell carcinoma of lung, excluding those with pericardial, pleural effusion, and those with contralateral hilar or contralateral supraclavicular lymph nodes. * Patients must have measurable disease according to RECIST criteria, and all detectable tumor can be encompassed by radiation therapy fields. * Weight loss ≦ 5% in the previous six months. * Patient must have adequate blood, liver, lungs and kidney function within the requirements of this study. * Female patients of child-bearing potential must test negative for pregnancy at the time of enrollment based on a serum pregnancy test. Male and female patients must agree to use a reliable method of birth control during and for 3 months following the last dose of study drug. * Patients must sign a study-specific informed consent form prior to study entry. Exclusion Criteria: * Complete tumor resection, recurrent disease, or those patients eligible for definitive surgery. * Previous chemotherapy or previous biologic response modifiers for current lung cancer. * Patient has previously had thoracic radiation therapy. * Prior or concurrent malignancy except non-melanomatous skin cancer unless disease-free for five years or more. * Serious concomitant disorders that would compromise the safety of the patient, or compromise the patient's ability to complete the study, at the discretion of the investigator. * History of significant neurological or mental disorder, including seizures or dementia.